drugset

drugset / Trial / NCT03416231

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

NCT03416231 ↗

Phase 2 Unknown 20 enrolled Afﬁliated Hospital of North Sichuan Medical College Jiangsu HengRui Medicine Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the effectiveness and safety of apatinib combined with docetaxel in NSCLC.

Timeline

Start: 2016-11-30
Primary completion: 2019-01-01
Completion: 2020-01-01

Publications

Jiang Q, Zhang NL, Ma DY, Tan BX, Hu X, Fang XD. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study. Medicine (Baltimore). 2019 Jun;98(26):e16065. doi: 10.1097/MD.0000000000016065.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	75 mg/m2	Intravenous
Subject	Rivoceranib	Small molecule	250 mg	Oral

Indications